Abbott Laboratories (ABT) Other Non-Current Liabilities (2009 - 2021)

Abbott Laboratories (ABT) has 13 years of Other Non-Current Liabilities data on file, last reported at $3.7 billion in Q4 2021.

• For the quarter ending Q4 2021, Other Non-Current Liabilities changed 0.03% year-over-year to $3.7 billion; the trailing twelve-month figure through Dec 2021 stood at $3.7 billion (changed 0.03% YoY), and the FY2021 full-year result was $3.7 billion, changed 0.03% from the prior year.
• Other Non-Current Liabilities steadied at $3.7 billion in Q4 2021, from $3.7 billion in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $4.9 billion in Q4 2017 to a low of $3.7 billion in Q4 2020.
• A 5-year average of $4.0 billion and a median of $3.9 billion in 2019 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities gained 6.73% in 2017 and fell 17.94% in 2018, its largest moves.
• Tracing ABT's Other Non-Current Liabilities over 5 years: stood at $4.9 billion in 2017, then slipped by 17.94% to $4.0 billion in 2018, then fell by 1.0% to $3.9 billion in 2019, then decreased by 6.59% to $3.7 billion in 2020, then rose by 0.03% to $3.7 billion in 2021.
• Business Quant data shows ABT's Other Non-Current Liabilities at $3.7 billion in Q4 2021, $3.7 billion in Q4 2020, and $3.9 billion in Q4 2019.